Neil Richmond
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Neil Richmond has a total of 110 co-authors. Here are the top co-authors by number of shared publications:
C. Walker
Northern Centre for Cancer Care, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, UK
6 shared publicationsC. Peedell
5 shared publicationsD. Shakespeare
4 shared publicationsJ. Green
4 shared publicationsK. Pilling
Northern Centre for Cancer Care, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK
4 shared publicationsChris Walker
Northern Centre for Cancer Care, Freeman Hospital, Newcastle upon Tyne, UK
3 shared publications
Latest Publications
- 22 April 2026
- Published by Elsevier in Medical Dosimetry
- Vol. 51 (3) , 350-354
Determination and use of patient curvature correction factors by measurement in electron monitor unit calculations
- 22 April 2026
- Published by Elsevier in Medical Dosimetry
- Vol. 51 (3) , 350-354
Determination and use of patient curvature correction factors by measurement in electron monitor unit calculations
- 30 August 2025
- Published by Springer Nature in Physical and Engineering Sciences in Medicine
- Vol. 48 (4) , 1893-1899
Measurement and application of the optimum value of head scatter correction factors in Radcalc for 6MV photon beams from varian linear accelerators
To determine the optimum value of head scatter correction factor (\(\:{S}_{c}^{corr}\)) used in Radcalc software. The head scatter factors for a selection of multi-leaf collimator fields were measured on a Varian TrueBeam Edge and TrueBeam linear accelerators using an ionisation chamber in a mini-phantom. Radcalc calculated the head scatter values for the same fields. Radcalc calculates head scatter as \(\:{S}_{c}=\:{S}_{c}^{mlc}+{S}_{c}^{corr}({S}_{c}^{open}-{S}_{c}^{mlc})\). The head scatter value from Radcalc was recorded when the value of \(\:{S}_{c}^{corr}\) was set to 0 or 1. An optimum value of \(\:{S}_{c}^{corr}\) was obtained by minimising the sum of the differences between measured and calculated. The optimum values of \(\:{S}_{c}^{corr}\), for each linear accelerator type, were applied to clinical patient volume modulated arc therapy calculations. Minimising the summed differences yielded optimum values of \(\:{S}_{c}^{corr}\) of 0.149 and 0.276 for the TrueBeam Edge and the TrueBeam datasets respectively. Applying these values to 100 clinical patient volume modulated arc therapy plans, for each linear accelerator type, reduced the mean difference between the primary calculation and the independent check from 0.55 ± 0.95% (µ ± σ) to −0.11 ± 0.85% for the TrueBeam Edge and from 0.79 ± 1.16% to 0.24 ± 0.90% for the TrueBeam plans compared to when a generic Sc value of 0.675 was used. Using optimal values of \(\:{S}_{c}^{corr}\:\)in Radcalc, determined by measurement, reduced the mean monitor unit difference when compared to the primary calculation of a treatment planning system compared to using the standard value of 0.675.- 30 August 2025
- Published by Springer Nature in Physical and Engineering Sciences in Medicine
- Vol. 48 (4) , 1893-1899
Measurement and application of the optimum value of head scatter correction factors in Radcalc for 6MV photon beams from varian linear accelerators
To determine the optimum value of head scatter correction factor (\(\:{S}_{c}^{corr}\)) used in Radcalc software. The head scatter factors for a selection of multi-leaf collimator fields were measured on a Varian TrueBeam Edge and TrueBeam linear accelerators using an ionisation chamber in a mini-phantom. Radcalc calculated the head scatter values for the same fields. Radcalc calculates head scatter as \(\:{S}_{c}=\:{S}_{c}^{mlc}+{S}_{c}^{corr}({S}_{c}^{open}-{S}_{c}^{mlc})\). The head scatter value from Radcalc was recorded when the value of \(\:{S}_{c}^{corr}\) was set to 0 or 1. An optimum value of \(\:{S}_{c}^{corr}\) was obtained by minimising the sum of the differences between measured and calculated. The optimum values of \(\:{S}_{c}^{corr}\), for each linear accelerator type, were applied to clinical patient volume modulated arc therapy calculations. Minimising the summed differences yielded optimum values of \(\:{S}_{c}^{corr}\) of 0.149 and 0.276 for the TrueBeam Edge and the TrueBeam datasets respectively. Applying these values to 100 clinical patient volume modulated arc therapy plans, for each linear accelerator type, reduced the mean difference between the primary calculation and the independent check from 0.55 ± 0.95% (µ ± σ) to −0.11 ± 0.85% for the TrueBeam Edge and from 0.79 ± 1.16% to 0.24 ± 0.90% for the TrueBeam plans compared to when a generic Sc value of 0.675 was used. Using optimal values of \(\:{S}_{c}^{corr}\:\)in Radcalc, determined by measurement, reduced the mean monitor unit difference when compared to the primary calculation of a treatment planning system compared to using the standard value of 0.675.- Open Access
- 30 August 2024
- Published by Elsevier in Radiography
- Vol. 30 (6) , 1677-1686
Cardiac SABR: Image matching techniques for accurate treatment delivery
- 30 August 2024
- Published by Elsevier in Radiography
- Vol. 30 (6) , 1677-1686
Open AccessCardiac SABR: Image matching techniques for accurate treatment delivery
- Open Access
- 24 October 2023
- Published by Oxford University Press (OUP) in British Journal of Radiology
- Vol. 96 (1152) , 20230004
An evaluation of an energy independent CT reconstruction algorithm for use in radiotherapy treatment planning
Objective: Radiotherapy treatment planning relies upon density information provided by CT for accurate dose calculations. Hounsfield units (HUs) are converted to electron/physical density via an energy dependant calibration curve. Multiple curves are required to make full use of the available accelerating potentials (kVp). The curves are bi-linear with a discontinuity occurring at soft-tissue densities. The commercial algorithm, DirectDensityTM (Siemens Healthcare GmbH), constructs a single calibration curve covering all available kVp. This enables the optimisation of the CT image quality, e.g. in terms of contrast, or the reduction of the imaging dose, whilst rendering the radiotherapy treatment dose calculation robust to the energy used to acquire the CT image. We report our investigations on the clinical utilisation of the DirectDensityTM algorithm for radiotherapy treatments, by using all accelerating potentials, i.e. from 70 kVp up to 140 kVp, available at our CT treatment simulator, in contrast to previous studies that were limited to accelerating potentials spanning a subset of the available kVp. Methods: The DirectDensityTM (DD) reconstruction algorithm available on a SOMATOM go.Open Pro CT scanner (Siemens Healthineers) was evaluated using the RayStation v. 9 treatment planning system (RaySearch Laboratories, Stockholm, Sweden) and a CIRS Model 002LFC IMRT Thorax Phantom (SunNuclear, Melbourne, FL), which was imaged at all available kVp with clinical protocols corresponding to various anatomical sites. The DD images were compared to those with the standard reconstruction algorithm acquired only at 120 kVp, as per our routine clinical practice. The effect of increasing kVp on HU is investigated for relevant tissue substitutes. In addition, a dosimetric comparison is performed for a VMAT plan technique with 6 MV X-rays using retrospective patient CT data sets representing four anatomical sites (pelvis, thorax, brain and “head and neck”) with five patients for each site. The original dose distributions were calculated on images acquired at 120 kVp using the standard clinical iterative reconstruction (Qr40) and compared with dose distributions recalculated on images reconstructed with the new DD (Sm40) algorithm. Results: The maximum difference for radiotherapy doses calculated using images of the phantom reconstructed with Qr40 (120 kVp) or DD (all available kVp) was 0.73%. The patient plans on the anatomically representative sites studied here showed a mean PTV dose difference of −0.2% (s.d. 0.7) for D99%, −0.4% (s.d. 0.4%) for D50% and −0.3% (s.d. 0.4%) for D2%. Incidentally, we found a previously unreported decrease in HU, mostly notable for bone type inserts (~34 HU (cortical bone)), at 110 kVp for the DD reconstructed images. The effect was not noted for the standard Qr40 reconstructions. Conclusion: DD has a minimal dosimetric impact in the dose calculations for radiotherapy treatments and could be implemented with existing clinical workflows. Attention should be paid to the HU values for images acquired at 110 kVp (DD algorithm), which warrants further investigation. Advances in knowledge: This is the first paper where DD was evaluated at all available kVp, leading to the incidental discovery of abnormal HU values at 110 kVp for this algorithm.
- 24 October 2023
- Published by Oxford University Press (OUP) in British Journal of Radiology
- Vol. 96 (1152) , 20230004
Open AccessAn evaluation of an energy independent CT reconstruction algorithm for use in radiotherapy treatment planning
Objective: Radiotherapy treatment planning relies upon density information provided by CT for accurate dose calculations. Hounsfield units (HUs) are converted to electron/physical density via an energy dependant calibration curve. Multiple curves are required to make full use of the available accelerating potentials (kVp). The curves are bi-linear with a discontinuity occurring at soft-tissue densities. The commercial algorithm, DirectDensityTM (Siemens Healthcare GmbH), constructs a single calibration curve covering all available kVp. This enables the optimisation of the CT image quality, e.g. in terms of contrast, or the reduction of the imaging dose, whilst rendering the radiotherapy treatment dose calculation robust to the energy used to acquire the CT image. We report our investigations on the clinical utilisation of the DirectDensityTM algorithm for radiotherapy treatments, by using all accelerating potentials, i.e. from 70 kVp up to 140 kVp, available at our CT treatment simulator, in contrast to previous studies that were limited to accelerating potentials spanning a subset of the available kVp. Methods: The DirectDensityTM (DD) reconstruction algorithm available on a SOMATOM go.Open Pro CT scanner (Siemens Healthineers) was evaluated using the RayStation v. 9 treatment planning system (RaySearch Laboratories, Stockholm, Sweden) and a CIRS Model 002LFC IMRT Thorax Phantom (SunNuclear, Melbourne, FL), which was imaged at all available kVp with clinical protocols corresponding to various anatomical sites. The DD images were compared to those with the standard reconstruction algorithm acquired only at 120 kVp, as per our routine clinical practice. The effect of increasing kVp on HU is investigated for relevant tissue substitutes. In addition, a dosimetric comparison is performed for a VMAT plan technique with 6 MV X-rays using retrospective patient CT data sets representing four anatomical sites (pelvis, thorax, brain and “head and neck”) with five patients for each site. The original dose distributions were calculated on images acquired at 120 kVp using the standard clinical iterative reconstruction (Qr40) and compared with dose distributions recalculated on images reconstructed with the new DD (Sm40) algorithm. Results: The maximum difference for radiotherapy doses calculated using images of the phantom reconstructed with Qr40 (120 kVp) or DD (all available kVp) was 0.73%. The patient plans on the anatomically representative sites studied here showed a mean PTV dose difference of −0.2% (s.d. 0.7) for D99%, −0.4% (s.d. 0.4%) for D50% and −0.3% (s.d. 0.4%) for D2%. Incidentally, we found a previously unreported decrease in HU, mostly notable for bone type inserts (~34 HU (cortical bone)), at 110 kVp for the DD reconstructed images. The effect was not noted for the standard Qr40 reconstructions. Conclusion: DD has a minimal dosimetric impact in the dose calculations for radiotherapy treatments and could be implemented with existing clinical workflows. Attention should be paid to the HU values for images acquired at 110 kVp (DD algorithm), which warrants further investigation. Advances in knowledge: This is the first paper where DD was evaluated at all available kVp, leading to the incidental discovery of abnormal HU values at 110 kVp for this algorithm.
- 8 May 2023
- Published by Elsevier in Medical Dosimetry
- Vol. 48 (4) , 216-224
Evaluation of the RadCalc collapsed cone dose calculation algorithm against measured data
- 8 May 2023
- Published by Elsevier in Medical Dosimetry
- Vol. 48 (4) , 216-224
Evaluation of the RadCalc collapsed cone dose calculation algorithm against measured data
- 1 February 2023
- Published by Elsevier in Radiography
- Vol. 29 (2) , 347-354
The first patients treated with MR-CBCT soft-tissue matching in a MR-only prostate radiotherapy pathway
- 1 February 2023
- Published by Elsevier in Radiography
- Vol. 29 (2) , 347-354
The first patients treated with MR-CBCT soft-tissue matching in a MR-only prostate radiotherapy pathway
- 1 February 2021
- Published by Elsevier in Physica Medica
- Vol. 82, 87-99
Comparison of the RayStation photon Monte Carlo dose calculation algorithm against measured data under homogeneous and heterogeneous irradiation geometries
- 1 February 2021
- Published by Elsevier in Physica Medica
- Vol. 82, 87-99
Comparison of the RayStation photon Monte Carlo dose calculation algorithm against measured data under homogeneous and heterogeneous irradiation geometries
- 24 September 2020
- Published by Oxford University Press (OUP) in British Journal of Radiology
- Vol. 94 (1117)
A systematic review and practical considerations of stereotactic body radiotherapy in the treatment of head and neck cancer
Objectives: Stereotactic radiotherapy (SBRT) is gaining popularity although its use in head and neck cancer (HNC) is not well defined. The primary objective was to review the published evidence regarding the use of stereotactic radiotherapy in HNC. Methods: A literature search was performed by using MEDLINE and EMBASE databases for eligible studies from 2000 to 2019 and 26 relevant studies were identified. Results: Literature demonstrates a heterogeneous use of this technique with regards to patient population, primary or salvage treatment, dose fractionation regimens, outcomes and follow-up protocols. Carotid blow out syndrome is a risk as with other forms of reirradiation but alternative treatment regimens may reduce this risk. Conclusion: At present there is a lack of evidence regarding SBRT as a primary treatment option for HNC and definitive answers regarding efficacy and tolerability cannot be provided but there is growing evidence that SBRT reirradiation regimens are safe and effective. In lieu of evidence from large Phase III trials, we define appropriate organ at risk constraints and prescription doses, with accurate plan summation approaches. Prospective randomised trials are warranted to validate improved treatment outcomes and acceptable treatment morbidity. Advances in knowledge: This article provides a comprehensive review of evidence of use of stereotactic radiotherapy in HNC site (either as a primary treatment or as reirradiation). We also provide an evidence–based approach to the implementation and practical consideration of stereotactic radiotherapy in HNC.
- 24 September 2020
- Published by Oxford University Press (OUP) in British Journal of Radiology
- Vol. 94 (1117)
A systematic review and practical considerations of stereotactic body radiotherapy in the treatment of head and neck cancer
Objectives: Stereotactic radiotherapy (SBRT) is gaining popularity although its use in head and neck cancer (HNC) is not well defined. The primary objective was to review the published evidence regarding the use of stereotactic radiotherapy in HNC. Methods: A literature search was performed by using MEDLINE and EMBASE databases for eligible studies from 2000 to 2019 and 26 relevant studies were identified. Results: Literature demonstrates a heterogeneous use of this technique with regards to patient population, primary or salvage treatment, dose fractionation regimens, outcomes and follow-up protocols. Carotid blow out syndrome is a risk as with other forms of reirradiation but alternative treatment regimens may reduce this risk. Conclusion: At present there is a lack of evidence regarding SBRT as a primary treatment option for HNC and definitive answers regarding efficacy and tolerability cannot be provided but there is growing evidence that SBRT reirradiation regimens are safe and effective. In lieu of evidence from large Phase III trials, we define appropriate organ at risk constraints and prescription doses, with accurate plan summation approaches. Prospective randomised trials are warranted to validate improved treatment outcomes and acceptable treatment morbidity. Advances in knowledge: This article provides a comprehensive review of evidence of use of stereotactic radiotherapy in HNC site (either as a primary treatment or as reirradiation). We also provide an evidence–based approach to the implementation and practical consideration of stereotactic radiotherapy in HNC.
- 18 July 2020
- Published by Wiley in Medical Physics
- Vol. 47 (10) , 4758-4762
Technical Note: Efficient and accurate MRI‐only based treatment planning of the prostate using bulk density assignment through atlas‐based segmentation
Purpose: This study investigates the dosimetric accuracy as well as the robustness of a bulk density assignment approach to magnetic resonance imaging (MRI)‐only based treatment planning of the prostate, with bulk density regions automatically identified using atlas‐based segmentation (ABS).Methods: Twenty prostate radiotherapy patients received planning computed tomography (CT) and MRI scans and were treated with volumetric modulated arc therapy (VMAT). Two bulk densities were set, one for bone and one for soft tissue. The bone contours were created by using ABS followed by manual modification if considered necessary.A range of soft tissue and bone density pairs, between 0.95 and 1.03 g/cm3 with increments of 0.01 for soft tissue, and between 1.15 and 1.65 g/cm3 with increments of 0.05 for bone, were evaluated. Using the density pair giving the lowest dose difference compared to the CT‐based dose, dose differences were calculated using both the manually modified bone contours and the bone contours from ABS. Contour overlap measurements between the ABS contours and the manually modified contours were calculated.Results: The dose comparison shows a very good agreement with the CT when using 0.98 g/cm3 for soft tissue and 1.20 g/cm3 for bone, with a dose difference less than 1 % in average dose in all regions of interest. The mean Dice similarity coefficient for bone was 0.94 and the Mean Distance to Agreement was <1 mm in most cases.Conclusions: Using bulk density assignment on MR images with suitable densities for bone and soft tissue results in clinically acceptable dose differences compared to dose calculated on the CT, for both atlas‐based and manual bone contours. This demonstrates that an integrated MRI‐only pathway utilizing a bulk density assignment for two tissue types is a feasible and robust approach for patients with prostate cancer treated with VMAT.
- 18 July 2020
- Published by Wiley in Medical Physics
- Vol. 47 (10) , 4758-4762
Technical Note: Efficient and accurate MRI‐only based treatment planning of the prostate using bulk density assignment through atlas‐based segmentation
Purpose: This study investigates the dosimetric accuracy as well as the robustness of a bulk density assignment approach to magnetic resonance imaging (MRI)‐only based treatment planning of the prostate, with bulk density regions automatically identified using atlas‐based segmentation (ABS).Methods: Twenty prostate radiotherapy patients received planning computed tomography (CT) and MRI scans and were treated with volumetric modulated arc therapy (VMAT). Two bulk densities were set, one for bone and one for soft tissue. The bone contours were created by using ABS followed by manual modification if considered necessary.A range of soft tissue and bone density pairs, between 0.95 and 1.03 g/cm3 with increments of 0.01 for soft tissue, and between 1.15 and 1.65 g/cm3 with increments of 0.05 for bone, were evaluated. Using the density pair giving the lowest dose difference compared to the CT‐based dose, dose differences were calculated using both the manually modified bone contours and the bone contours from ABS. Contour overlap measurements between the ABS contours and the manually modified contours were calculated.Results: The dose comparison shows a very good agreement with the CT when using 0.98 g/cm3 for soft tissue and 1.20 g/cm3 for bone, with a dose difference less than 1 % in average dose in all regions of interest. The mean Dice similarity coefficient for bone was 0.94 and the Mean Distance to Agreement was <1 mm in most cases.Conclusions: Using bulk density assignment on MR images with suitable densities for bone and soft tissue results in clinically acceptable dose differences compared to dose calculated on the CT, for both atlas‐based and manual bone contours. This demonstrates that an integrated MRI‐only pathway utilizing a bulk density assignment for two tissue types is a feasible and robust approach for patients with prostate cancer treated with VMAT.
- 24 April 2020
- Published by Oxford University Press (OUP) in British Journal of Radiology
- Vol. 93 (1111) , 20200142
A UK wide study of current prostate planning practice
Objectives: The objective of this work was to undertake a non-judgemental study of prostate planning practice across the UK by inviting all departments to undertake the same case. Methods: An invitation to take part in the study was sent to the Heads of all UK radiotherapy departments and posted on the UK Medical Physics mailbase. Individuals interested in participating were able to access a single anonymised CT dataset for download with the prostate gland, seminal vesicles, bladder, rectum, bowel, femoral heads, and penile bulb outlined. A brief patient history was also supplied. Participants were asked to create planning target volumes (PTVs) according to their local clinical protocol and plan to give 60 Gy in 20 fractions to the PTV receiving the highest dose. No guidance was given for acceptable organ at risk doses. Dicom plan and dose information was loaded back into ProKnow for analysis by contributors. Results: There were 102 plan submissions made to the study representing 48 different UK radiotherapy departments. Seventeen distinct methodologies for creating the prescription PTV from the prostate and seminal vesicles were identified with the ethos of the CHHIP trial protocol for margin growing followed in nearly two-thirds of cases. Positive correlations were found when assessing the doses received by the bladder and rectum against the volume of the PTV to which 60 Gy was prescribed. Conclusions: A national planning study whereby staff from a multitude of radiotherapy departments create plans based solely on a single dataset is feasible. The cohort of data was made available to all participants following the study to enable self-assessment and benchmarking against that of their peers. Advances in knowledge: This is the first UK wide treatment planning study to investigate local clinical prostate planning practice. This has given UK departments the opportunity to evaluate their planning practices against those of their peers.
- 24 April 2020
- Published by Oxford University Press (OUP) in British Journal of Radiology
- Vol. 93 (1111) , 20200142
A UK wide study of current prostate planning practice
Objectives: The objective of this work was to undertake a non-judgemental study of prostate planning practice across the UK by inviting all departments to undertake the same case. Methods: An invitation to take part in the study was sent to the Heads of all UK radiotherapy departments and posted on the UK Medical Physics mailbase. Individuals interested in participating were able to access a single anonymised CT dataset for download with the prostate gland, seminal vesicles, bladder, rectum, bowel, femoral heads, and penile bulb outlined. A brief patient history was also supplied. Participants were asked to create planning target volumes (PTVs) according to their local clinical protocol and plan to give 60 Gy in 20 fractions to the PTV receiving the highest dose. No guidance was given for acceptable organ at risk doses. Dicom plan and dose information was loaded back into ProKnow for analysis by contributors. Results: There were 102 plan submissions made to the study representing 48 different UK radiotherapy departments. Seventeen distinct methodologies for creating the prescription PTV from the prostate and seminal vesicles were identified with the ethos of the CHHIP trial protocol for margin growing followed in nearly two-thirds of cases. Positive correlations were found when assessing the doses received by the bladder and rectum against the volume of the PTV to which 60 Gy was prescribed. Conclusions: A national planning study whereby staff from a multitude of radiotherapy departments create plans based solely on a single dataset is feasible. The cohort of data was made available to all participants following the study to enable self-assessment and benchmarking against that of their peers. Advances in knowledge: This is the first UK wide treatment planning study to investigate local clinical prostate planning practice. This has given UK departments the opportunity to evaluate their planning practices against those of their peers.